comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 11:58:30 - browse：2

Boston Globe

A commonly prescribed medication for children’s asthma is disappearing from pharmacists’ shelves, forcing parents and pediatricians to scramble for alternatives just as allergy season is about to start.

In a move unusual for such a widely used drug, GlaxoSmithKline discontinued Flovent HFA, the brand name of its corticosteroid treatment fluticasone propionate, at the end of December. Critics, including Massachusetts Senator Elizabeth Warren, say the decision helps the company avoid new Medicaid penalties going into effect this year for medications with price increases that outpace inflation.

“It was all very confusing, and we were left scrambling, trying to find out what we could do,” said Simone Fung, whose 5-year-old son, David, endured worse asthma symptoms over the past two months as the Cambridge family navigated confusing insurance policies and shortages of alternative medications to find a replacement for Flovent.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Coercive sterilizations revealed by STAT prompt outrage

hotspot

WSS

Teladoc has a new CEO, but challenges remain the same

Report captures long Covid’s disabling effects and policy challenges

Hubble vs. James Webb telescope images: See the difference

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

5 takeaways from STAT's examination of Zynex Medical

Vertex cell therapy lets patients with type 1 diabetes stop insulin

hotspot

comprehensive

explore

Apple is now the first public company to be valued at $3 trillion

Dexcom's push to bring CGM to type 2 diabetes patients

How one medical school became remarkably diverse

The system is set up to fail children with medical complexity

Sports medicine is finally prioritizing gender equality

5 takeaways from STAT's examination of Zynex Medical

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Dexcom's push to bring CGM to type 2 diabetes patients

23andMe had bad news about my health. I wish a person had delivered it

Health care court cases: Humana, Sutter, Novant

knowledge

STAT wants to know your pick for a great summer read or listen

UpToDate has a racism problem: Dr. Stanley Goldfarb

Pharma companies must ensure equitable access to obesity drugs

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

NIH tests clinical research in primary care with $30 million program

Prescription digital therapeutics are key to pharma’s future

hotspot

Wikipedia

leisure time

explore